Literature DB >> 21921264

Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue.

Malte Tiburcy1, Michael Didié, Oliver Boy, Peter Christalla, Stephan Döker, Hiroshi Naito, Bijoy Chandapillai Karikkineth, Ali El-Armouche, Michael Grimm, Monika Nose, Thomas Eschenhagen, Anke Zieseniss, Doerthe M Katschinksi, Nazha Hamdani, Wolfgang A Linke, Xiaoke Yin, Manuel Mayr, Wolfram-Hubertus Zimmermann.   

Abstract

RATIONALE: Cardiac tissue engineering should provide "realistic" in vitro heart muscle models and surrogate tissue for myocardial repair. For either application, engineered myocardium should display features of native myocardium, including terminal differentiation, organotypic maturation, and hypertrophic growth.
OBJECTIVE: To test the hypothesis that 3D-engineered heart tissue (EHT) culture supports (1) terminal differentiation as well as (2) organotypic assembly and maturation of immature cardiomyocytes, and (3) constitutes a methodological platform to investigate mechanisms underlying hypertrophic growth. METHODS AND
RESULTS: We generated EHTs from neonatal rat cardiomyocytes and compared morphological and molecular properties of EHT and native myocardium from fetal, neonatal, and adult rats. We made the following key observations: cardiomyocytes in EHT (1) gained a high level of binucleation in the absence of notable cytokinesis, (2) regained a rod-shape and anisotropic sarcomere organization, (3) demonstrated a fetal-to-adult gene expression pattern, and (4) responded to distinct hypertrophic stimuli with concentric or eccentric hypertrophy and reexpression of fetal genes. The process of terminal differentiation and maturation (culture days 7-12) was preceded by a tissue consolidation phase (culture days 0-7) with substantial cardiomyocyte apoptosis and dynamic extracellular matrix restructuring.
CONCLUSIONS: This study documents the propensity of immature cardiomyocytes to terminally differentiate and mature in EHT in a remarkably organotypic manner. It moreover provides the rationale for the utility of the EHT technology as a methodological bridge between 2D cell culture and animal models.

Entities:  

Mesh:

Year:  2011        PMID: 21921264     DOI: 10.1161/CIRCRESAHA.111.251843

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  43 in total

1.  Microdomain heterogeneity in 3D affects the mechanics of neonatal cardiac myocyte contraction.

Authors:  Matthew W Curtis; Elisa Budyn; Tejal A Desai; Allen M Samarel; Brenda Russell
Journal:  Biomech Model Mechanobiol       Date:  2012-03-11

2.  Myocyte-depleted engineered cardiac tissues support therapeutic potential of mesenchymal stem cells.

Authors:  Gregory W Serrao; Irene C Turnbull; Damian Ancukiewicz; Do Eun Kim; Evan Kao; Timothy J Cashman; Lahouaria Hadri; Roger J Hajjar; Kevin D Costa
Journal:  Tissue Eng Part A       Date:  2012-06-25       Impact factor: 3.845

3.  Trichostatin A enhances differentiation of human induced pluripotent stem cells to cardiogenic cells for cardiac tissue engineering.

Authors:  Shiang Y Lim; Priyadharshini Sivakumaran; Duncan E Crombie; Gregory J Dusting; Alice Pébay; Rodney J Dilley
Journal:  Stem Cells Transl Med       Date:  2013-07-24       Impact factor: 6.940

4.  Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling.

Authors:  Oscar J Abilez; Evangeline Tzatzalos; Huaxiao Yang; Ming-Tao Zhao; Gwanghyun Jung; Alexander M Zöllner; Malte Tiburcy; Johannes Riegler; Elena Matsa; Praveen Shukla; Yan Zhuge; Tony Chour; Vincent C Chen; Paul W Burridge; Ioannis Karakikes; Ellen Kuhl; Daniel Bernstein; Larry A Couture; Joseph D Gold; Wolfram H Zimmermann; Joseph C Wu
Journal:  Stem Cells       Date:  2017-11-13       Impact factor: 6.277

5.  Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium.

Authors:  Irene C Turnbull; Ioannis Karakikes; Gregory W Serrao; Peter Backeris; Jia-Jye Lee; Chaoqin Xie; Grant Senyei; Ronald E Gordon; Ronald A Li; Fadi G Akar; Roger J Hajjar; Jean-Sébastien Hulot; Kevin D Costa
Journal:  FASEB J       Date:  2013-10-30       Impact factor: 5.191

6.  S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.

Authors:  Julia Ritterhoff; Mirko Völkers; Andreas Seitz; Kristin Spaich; Erhe Gao; Karsten Peppel; Sven T Pleger; Wolfram H Zimmermann; Oliver Friedrich; Rainer H A Fink; Walter J Koch; Hugo A Katus; Patrick Most
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

Review 7.  Myocardial Tissue Engineering for Regenerative Applications.

Authors:  Buntaro Fujita; Wolfram-Hubertus Zimmermann
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

Review 8.  In vitro models of the cardiac microenvironment to study myocyte and non-myocyte crosstalk: bioinspired approaches beyond the polystyrene dish.

Authors:  Celinda M Kofron; Ulrike Mende
Journal:  J Physiol       Date:  2017-02-27       Impact factor: 5.182

9.  Robust T-tubulation and maturation of cardiomyocytes using tissue-engineered epicardial mimetics.

Authors:  Weining Bian; Nima Badie; Herman D Himel; Nenad Bursac
Journal:  Biomaterials       Date:  2014-02-06       Impact factor: 12.479

Review 10.  Myocardial tissue engineering: in vitro models.

Authors:  Gordana Vunjak Novakovic; Thomas Eschenhagen; Christine Mummery
Journal:  Cold Spring Harb Perspect Med       Date:  2014-03-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.